Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Cost of sales as % of net product sales by Year
Cost of sales as % of net product sales (%) (%)
Moderna Cost of sales as % of net product sales: 48.0% in FY2025, up 1.0 pts from a year earlier.
Latest, FY2025
48.0%
Period ended Dec 31, 2025
Change on a year earlier
+1.0 pts
47.0% in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Where the FY2025 figure comes from
“Cost of sales for 2025 decreased by $596 million, or 41%, compared to 2024. As a percentage of net product sales, cost of sales was 48% in 2025 compared to 47% in 2024, remaining relatively consistent year over year.”
Source: FY2025 10-K ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of sales as % of net product sales (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.0% | +1.0 pts | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 47.0% | -23.0 pts | FY2025 10-K ↗ |
| FY2023 | Dec 31, 2023 | 70.0% | +41.0 pts | FY2023 10-K ↗ |
| FY2022 | Dec 31, 2022 | 29.0% | +14.0 pts | FY2022 10-K ↗ |
| FY2021 | Dec 31, 2021 | 15.0% | – | Q4 2021 Earnings Release (8-K) ↗ |
Cite this data
StockData. (2026). Moderna Cost of sales as % of net product sales (%), annual FY2021–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-pct-sales
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.